All In Biotech

BLA 761291 · Janssen Biotech

Tecvayli

Teclistamab-Cqyv · Injection

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

CDER novel approval, Oct 25, 2022: To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Oct 25, 2022

Approved uses

4

Original approval plus efficacy supplements

Registered trials

63

13 Phase 3, 32 recruiting

FAERS reports

2,379

1,947 serious, 444 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.5) and Warnings and Precautions (5.1) ] . Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious, life-threatening, or fatal reactions, can occur in patients receiving TECVAYLI. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI until neurologic toxicity resolves or permanently discontinue based on severity [see Dosage and...

What it is approved for

From the label in effect Mar 10, 2026.

TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma: in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent ( 1 ). as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody ( 1 ).

Mechanism: Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro , teclistamab-cqyv activated T-cells, caused the release of various proinflammatory cytokines, and resulted in the lysis of multiple myeloma cells.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 5, 2026 Supplement 18 · Efficacy · priority review Breakthrough therapyOrphanLetterLabelMedication Guide
  • Nov 22, 2024 Supplement 9 · Efficacy OrphanLetter
  • Feb 20, 2024 Supplement 3 · Efficacy OrphanLetterLabel
  • Oct 25, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • TECVAYLI · TECLISTAMAB-CQYV 30MG/3ML(10MG/ML) · INJECTABLE, INJECTION · Prescription
  • TECVAYLI · TECLISTAMAB-CQYV 153MG/1.7ML(90MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Teclistamab" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cytokine release syndrome582
  • immune effector cell-associated neurotoxicity syndrome211
  • off label use199
  • death155
  • infection136
  • plasma cell myeloma131
  • neutropenia116
  • fatigue99
  • pyrexia94
  • pneumonia92
  • covid-1988
  • drug ineffective73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202211
2023408
2024616
2025772
2026572

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tecvayli (Teclistamab-Cqyv)

2024 spending

$966K

Beneficiaries

13

66 claims

Per beneficiary

$74,314

$4,810.76 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$289,558
2024$966,087

Part B: Tecvayli (Teclistamab-Cqyv) · HCPCS J9380

2024 spending

$200M

Beneficiaries

1,549

19,555 claims

Per beneficiary

$129,048

2024 ASP limit $31.33 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$88,245,815
2024$199,895,746

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 35 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.